<scp>AIDE</scp>: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials
Yanhong Zhou(Eli Lilly (United States)), Zeena Salman(Revolution Medicines (United States)), Ying Yuan(The University of Texas MD Anderson Cancer Center), Li Wang(AbbVie (United States)), Sudhir Penugonda(ClearMotion (United States)), Greg Cicconetti(AbbVie (United States)), Yunming Mu(Revolution Medicines (United States)), Yujie Zhao(Zhengzhou University)
Cited by 6
Related Papers
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937
The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation
|AIDS|2014|385
Joint Regression Analysis of Correlated Data Using Gaussian Copulas
|Biometrics|2008|207
Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis.
|Proceedings of the National Academy of Sciences|1995|196